Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
60 Leser
Artikel bewerten:
(0)

Dotmatics Partners with BioByte to Offer ClogP Across the Entire Dotmatics Platform

BISHOPS STORTFORD, England and CLAREMONT, California, April 5, 2016 /PRNewswire/ --

Users of Vortex, Browser and Dotmatics for Office can now calculate Hydrophobicity using the industry standard ClogP by BioByte

Dotmatics, a leading provider of scientific informatics solutions and services to the life sciences industry, announced a partnership with BioByte , producer of the industry gold standard partition coefficient calculator (ClogP).This deal will enable users of the Dotmatics Platform including Vortex and Browser to calculate ClogP seamlessly within the applications. This will streamline the research process and speed up the selection of potential drug candidates.

LogP is one of the parameters most intensively used during the drug discovery process to filter out compounds with low prospects of becoming a drug. It helps to define the chemical space in which to work. Most discovery programs that are focused on small molecules rely on predicted LogP. BioByte's ClogP has been the benchmark calculator in drug discovery research for the last 35 years. ClogP is a part of BioByte's Bio-Loom suite of calculators and is the most extensively tested fragment-based LogP calculator used in the industry. ClogP uses a rational constructionist approach, incorporating tens of thousands of carefully curated measured values and interaction factors, all of which are based on physical chemistry.

This partnership allows Dotmatics to add ClogP to the substantial list of calculators already available across the Dotmatics Platform. ClogP will complement the atom-based XlogP method enabling customers to compare and establish consensus on the value of LogP in order to determine the profile of compounds more accurately.

"Integrating ClogP within Vortex and Browser has been one of the top requests from our customers", said Dr Mike Hartshorn, CSO at Dotmatics. "The partnership with BioByte will enable us to offer users the ability to access the ClogP calculator without having to leave their favourite interface. We are committed to offer outstanding quality throughout the Dotmatics Platform and ClogP by BioByte is a great addition to our suite, matching the standardof our solutions."

"The partnership with Dotmatics will enable us to expand the already ubiquitous presence of ClogP in Pharma and Biotech," said Albert Leo, CEO of BioByte. "During the past 35 years, we have invested and continue to invest a large amount of effort enriching our programs and databases. The partnership guarantees to our users that the calculator remains the best in the market. We hope that the users of the Dotmatics Platform will takeadvantage of the extensive experience ClogP provides within their day to day research."

About BioByte:

BioByte was formed in 1993 by Drs. Corwin Hansch and Albert Leo to carry on the legacy and work of their groundbreaking Medicinal Chemistry Project, which they founded at Pomona College in the early 1970s. BioByte's flagship program is Bio-Loom, which combines the gold standard ClogP and CMR calculators with access to the Masterfile and CQSAR databases and related tools. For more information, contact Michael Medlin atmmedlin@biobyte.com, or visit their website: www.biobyte.com

About Dotmatics:

Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Dotmatics' enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, Mac OS X and Linux. A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK. Visitdotmatics.com

For More Information Please Contact:
Marla Kertzman for Dotmatics
pr@dotmatics.com
+1-209-852-9027
Michael L. Medlin for BioByte
mmedlin@biobyte.com
+1-909-624-5992

© 2016 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.